Identification of β2 microglobulin, the product of B2M gene, as a Host Factor for Vaccinia Virus Infection by Genome-Wide CRISPR genetic screens

Alejandro Matía1*, Maria M. Lorenzo1*, Yolimar C. Romero-Estremera1*, Juana M. Sánchez-Puig1, Angel Zaballos2, Rafael Blasco1*

1 Departamento de Biotecnología, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria–Consejo Superior de Investigaciones Científicas (INIA–CSIC), Madrid, Spain, 2 Unidad de Genómica, Centro Nacional de Microbiología–ISCIII, Madrid, Spain

☯ These authors contributed equally to this work.
¤ Current address: University of Puerto Rico, San Juan, Puerto Rico.
* blasco@inia.csic.es

Abstract

Genome-wide genetic screens are powerful tools to identify genes that act as host factors of viruses. We have applied this technique to analyze the infection of HeLa cells by Vaccinia virus, in an attempt to find genes necessary for infection. Infection of cell populations harboring single gene inactivations resulted in no surviving cells, suggesting that no single gene knock-out was able to provide complete resistance to Vaccinia virus and thus allow cells to survive infection. In the absence of an absolute infection blockage, we explored if some gene inactivations could provide partial protection leading to a reduced probability of infection. Multiple experiments using modified screening procedures involving replication restricted viruses led to the identification of multiple genes whose inactivation potentially increase resistance to infection and therefore cell survival. As expected, significant gene hits were related to proteins known to act in virus entry, such as ITGB1 and AXL as well as genes belonging to their downstream related pathways. Additionally, we consistently found β2-microglobulin, encoded by the B2M gene, among the screening top hits, a novel finding that was further explored. Inactivation of B2M resulted in 54% and 91% reduced VV infection efficiency in HeLa and HAP1 cell lines respectively. In the absence of B2M, while virus binding to the cells was unaffected, virus internalization and early gene expression were significantly diminished. These results point to β2-microglobulin as a relevant factor in the Vaccinia virus entry process.

Author summary

Orthopoxviruses, a genus belonging to the family Poxviridae, includes human pathogens like Variola virus, the causative agent of the now eradicated Smallpox, and Monkeypox virus that cause human outbreaks of zoonotic origin. Being the prototype Poxvirus,
**Vaccinia virus** has been extensively used as the ideal model to study infection. For Poxviruses, both fluid phase endocytosis and direct fusion at the plasma membrane have been described as modes of entry. To date, only a few cellular factors have been identified in the Vaccinia virus entry pathway. In this study, we report that blind genome-wide genetic screens allowed us to identify several cellular factors involved in Vaccinia virus infection, of which many could be related to known factors in virus entry. In addition, we found that \( \beta_2 \)-microglobulin constitutes a novel player for Poxvirus entry not related to previously described cellular pathways involved in the entry process. These findings add new information to the complex picture of Poxvirus entry and open the door to the discovery of new entry mechanisms used by Poxviruses.

**Introduction**

Poxviruses are dsDNA virus whose replication cycle occur entirely in the cytoplasm of the host cell [1,2]. Among the Poxviruses, Vaccinia virus (VV)–which was long used as vaccine against Smallpox- is the prototype poxvirus, and is the best characterized member of the family [1].

VV entry into cells is a complex process that has been subject to numerous studies. The VV size -approximately 360 nm of diameter- has led to the assumption that its entry into the cell cannot happen through caveolin or clathrin vesicles [3]. VV attachment to the cell is thought to occur with glycosaminoglycans and laminin [4,5]. Also, several membrane proteins have been proposed to serve as VV entry receptors, co-receptors or functional signaling ligands [6–8], in a process that leads to VV internalization through fluid phase endocytosis [9–13] followed by membrane fusion. As an alternative route, direct membrane fusion at plasma membrane has also been found to be a way of VV entry to the cytoplasmic space [14–17].

Surprisingly, VV entry process varies significantly between different cell lines, virus strains and viral forms [3,16,18–20]. Taken together, these observations point to the existence of several pathways leading to VV entry, which probably contribute to the broad tropism range of VV.

Genome-wide genetic screens have become an important tool to identify factors that are involved in biological processes. Several technologies, like RNA interference or insertional inactivation have been used to carry out high throughput screens. Recently, tools for the use of CRISPR/Cas gRNA libraries have allowed for a more targeted way of screening genes by inactivation, down-regulation or induction. Several high-throughput screenings using CRISPR/Cas9 technology have been performed to target cellular factors involved in infection viruses like SARS-CoV-2, West Nile virus, Influenza A virus, Human cytomegalovirus and Zika virus among others, revealing many host cell factors involved in viral infection [21–26]. In order to unravel the complexity of virus-cell interactions in Poxvirus infection, both RNAi [27–30] and retroviral-mediated insertional mutagenesis DNA [31,32] have been performed. Overall, the most important hits from those studies include entry factors and cellular genes somehow involved in viral morphogenesis.

We have developed a genome-wide CRISPR/Cas9-based screening using a human genome-wide sgRNA GeCKO library that depends on Cas9 expression and delivery of a sgRNA library into cells for target gene deletion [33,34]. The GeCKO library, designed to target all the genes of the human genome was used to obtain a pooled population of single-gene knock-outs that was then subject to Vaccinia virus infection. Through this approach, we have identified B2M as a pro-viral factor related to Vaccinia virus entry. Notably, B2M encodes the well characterized \( \beta_2 \)-microglobulin, a molecular chaperone known to form complexes with multiple
partners, including HLA, HFE, FcRn, MR1 (Human Leukocyte Antigen, Hereditary hemochromatosis protein, Neonatal Fc Receptor and Major histocompatibility complex class I-related gene protein). For those proteins, interaction with B2M is needed to reach the cell membrane [35–38]. We show herein that inactivation of B2M gene greatly impairs VV infection and viral production by affecting viral entry.

Results

Genetic screen reveals a set of hits potentially involved in VV infection

A loss of function, genome-wide screen was carried out by infecting a pooled population of cells harboring single gene KOs. The cell population was obtained by using a lentiviral library of 123,411 sgRNAs covering 19,050 genes and 1,864 miRNAs in the human genome [33]. HeLa cells constitutively expressing Cas9 were transduced with the lentiviral-sgRNA library, and passaged for 7–14 days in selective media. Of note, inactivation of genes essential for cell survival or growth are eliminated by this procedure, and therefore the screen is directed to the part of the genome that is non-essential in cell culture, which constitutes about 90% of the cellular genes [39,40].

We initially screened for gene KOs that could render the cells resistant to VV infection (Fig 1). However, several experiments performed by infecting with VV strain WR under various multiplicities of infection resulted in complete cell death at 48–72 h.p.i. Even low m.o.i. resulted in no surviving cells, indicating that no single gene KO was sufficient to completely block infection. This result was consistent with a possible lack of complete resistance to infection by gene inactivation, in agreement with previous results [32]. Given that the replicative strain WR was used, we reasoned that even if some degree of resistance would be present in

![Diagram of pooled genetic screen](https://doi.org/10.1371/journal.ppat.1010800.g001)

Fig 1. Design of the pooled genetic screen for the identification of VV pro-viral factors. A pool of cells with single gene inactivations was obtained by transducing the GeCKO sgRNA lentiviral library. Subsequently, the cell population is subjected to consecutive rounds of infection to enrich for resistant cells. Surviving cells are analyzed by high-throughput sequencing of the sgRNA region in the integrated lentiviral construct, which was amplified by PCR. Finally, results are analyzed using MaGeCK and ScreenBEAM algorithms for hit determination.
certain cells of the pool, the progeny virus in the cultures could lead to the death of initially surviving cells because of a second round of infection. In any event, based on these results, we concluded that probably only partial resistance could be achieved by single gene inactivations.

To search for pro-viral genes whose inactivation might lead to partial resistance to infection, we adapted our screen by introducing three main modifications: 1) we aimed at using large cell populations and controlled m.o.i. to infect only a portion of the cells, 2) we performed several consecutive rounds of infection to enhance the enrichment effect and 3) we used viruses with limited replication or production of extracellular virus to prevent the death of the surviving cells by infection with progeny virus.

For the ensuing experiments, viruses with limited spread ability in the culture were used. A virus deficient in genes A27L and F13L (V-ΔA27-ΔF13), which has a defect in the production of extracellular virus particles limiting its transmission [41,42]; and a virus deficient in the D4R gene (V-ΔD4), which is blocked in DNA replication of the viral genome and therefore is unable to generate infectious progeny virus [43]. In the case of the latter, a complementing HeLa cell line constitutively expressing VV D4 protein (HeLa-D4) was engineered to allow virus expansion in a similar way to previously reported [44]. Using those two virus mutants and different m.o.i.s, a number of experiments were completed (S1 Table), in which surviving cells were expanded, and analyzed. In parallel, uninfected cells were passaged for two weeks and used as control.

High throughput sequencing results for the sgRNA region amplified by PCR were subjected to bioinformatics analysis. Our computational analysis using MaGeCK [45,46] algorithm allowed us to identify genes that were enriched with respect to the initial cell pool. Fig 2A shows the analysis of a particular experiment and S2 Table shows the results from all experiments. Applying a False Discovery Rate (FDR) cutoff < 0.05 in MaGeCK analysis and log 2-fold change (LFC) > 0, hits from each experiment were selected (Fig 2B left panel). Considering that some gene knockouts can lead to enhanced growth and cell division over time, we carried out a control experiment in which the cell pool was passaged to assess the enrichment or depletion of those gene knockouts in the absence of infection (Fig 2B right panel), which was similar to the published screen results in public databases (i.e. DepMap Portal) [47]. We also used ScreenBEAM algorithm [48] (S3 Table) obtaining similar hits as with MaGeCK. A clustering analysis was performed but we could not detect an association of the hits obtained with the virus mutant or the m.o.i. used during selection (S2 Fig). The results from different infection experiments and from the control uninfected cultures are summarized in Fig 2B and led to a refined list of possible pro-viral genes.

Functional protein networks

Gene hits from multiple experiments were analyzed using the ReactomePA software to identify regulatory pathways (Figs 3 and 4 and S4 Table). Several high significance hits (FDR < 0.05 and LFC > 0) included genes previously described to play a role in the initial steps of VV infection such as ITGB1 or AXL [6,8], as well as genes encoding proteins involved in their downstream pathways. For instance, integrin alpha subunits (ITGA3, ITGAV and ITGA9) and actin cytoskeleton remodeling proteins (ACTG1, WASF2, ARPC2, ARPC3, ARPC4 . . . ) are related to the ITGB1/AXL and AKT activation pathway (Fig 4). Other of our strongest hits is CMIP, a poorly studied gene that is downstream-related to ITGB1 pathway [49,50]. Although weaker hits, two annexins were also identified with ScreenBEAM algorithm (ANXA2 and ANXA8L2), as was a member of the S100 family (S100A5) known to interact with annexins [51,52]. Annexins are commonly used to block phosphatidylserine due to its specific binding, and have been shown to reduce VV infectivity when pretreating VV mature virion with Annexin 5 [12].
Fig 2. Hit identification. A) Example of results obtained in one screen experiment (1_1) analyzed with MaGeCK. Hits with FDR < 0.05 are labelled with gene name tags. B) Heatmap summarizing the 27 experiments/experiment variations. Experiments are named with the starting cell pool followed by a number for the conditions used for that particular sample (see S1 Table). Genes with FDR < 0.05 in at least 1 experiment are included in the analysis. Enrichment results after selection are shown in the left panel as a heatmap representing the gene rank obtained with MaGeCK. For comparison, the right panel shows the log2-fold change for each gene in non-infected control experiment. Dots to the right of the red dotted line indicate enrichment in non-
infected cultures for that particular gene inactivation. For instance, CMIP KOs are depleted from the pool during passages in the absence of infection, whereas CSK KOs are enriched.

https://doi.org/10.1371/journal.ppat.1010800.g002

Other hits were related to additional pathways known to be important during infection, like the proteasome-ubiquitin pathway. KCTD5 emerged as one of the strongest hits, although it showed some enrichment in uninfected controls. Remarkably, KCTD5 protein has been proposed to be an adaptor for cullin3 ubiquitin ligases and is known to modulate the activity of Rac1 protein, a GTPase involved in VV internalization [53,54].

Interestingly, B2M (the gene encoding β2-microglobulin) was among the best hits. When analyzing the top 1% genes in the MaGeCK rank by Reactome Pathway Analysis [55] the B2M-related ‘Class I MHC mediated antigen processing & presentation’ pathway was the most prominent (Fig 3 and S4 Table). Enriched genes associated to this pathway were B2M, UBE4A, CUL3, KLHL22, PSME1, UBE2F, RNF41, PSMC3, TRIM4, PSMA8, TRIP12, ASB17. All of them except B2M belong to proteasome/ubiquitin ligases pathway, whereas B2M is more related to post antigen-processing and class I MHC loading stage.

Given that B2M likely represented a novel player in VV entry, we reviewed the screening results to check if genes related to B2M were also positive in the screen. Notably, although with lower significance, TAPBP was detected in ScreenBEAM analysis (S3 Table). Other B2M related genes coding proteins like Antigen peptide transporter 2 (TAP2), Protein disulfide-isomerase A6 (PDI6) and BiP chaperone (HSPA5) had good scores, even though their respective FDRs (MaGeCK) or ranking criteria (ScreenBEAM) were below our initial cutoff. Those

Fig 3. Pathway analysis. Reactome Pathway Analysis was performed using the top 1% list of genes according to MaGeCK rank. Class I MHC mediated antigen processing & presentation pathway was the most enriched pathway with 12 genes and p-adjust value < 0.05. Genes associated to this pathway by Reactome Pathway Analysis were B2M, UBE4A, CUL3, KLHL22, PSME1, UBE2F, RNF41, PSMC3, TRIM4, PSMA8, TRIP12, ASB17.

https://doi.org/10.1371/journal.ppat.1010800.g003
results reinforce the notion that B2M and its related pathway are bona-fide pro-viral factors as revealed by the survival screen. B2M protein is known to bind a number of proteins that include HLA molecules, HFE or FcRn. We individually tested the scores for those genes but did not find any of those significantly enriched in the screening. Notably, published results on experimental infections of B2M deficient mice reported unexpected levels of resistance to VV [56,57], phenotypes that now might be reasoned to be influenced by B2M absence.

**B2M KO impairs VV infection**

The screen results point at B2M as a relevant novel factor in VV infection. To further study its role in VV infection, we obtained HeLa and HAP1 KO cell lines by CRISPR/Cas9-mediated gene-inactivation. Inactivation of B2M gene was confirmed by sequencing of the mutated region in HeLa and HAP1 cells lines, and loss of expression was followed by Western blot and immunofluorescence analysis in HeLa clones (Fig 5A and 5B). Low multiplicity infections (m.o.i. = 0.05) of those clones led to a decrease in progeny virus, indicating an effect of B2M absence on VV infection (Fig 5C). Those results were confirmed in two independent cell clones (2.18- and 1.64-fold reduction). The reduction in virus production as a result of B2M gene inactivation was also confirmed in the background of a second cell line, HAP1 (Fig 5D and 5E).

Since ITGB1 has been described to be involved in VV entry [6], we were interested in studying whether the function of B2M and ITGB1 are overlapping. Infection of ITGB1 KO, B2M KO, and B2M/ITGB1 double KO (DKO) cell clones in the HAP1 cells at low m.o.i. with a GFP-expressing VV revealed a significant reduction associated with B2M inactivation, and a smaller effect associated to ITGB1 inactivation, as measured by both viral production and GFP expression (Fig 5D and 5E). Concurrent inactivation of B2M and ITGB1 genes did not result in enhanced reduction when compared with B2M inactivation alone. We additionally tested if plaque size or number were affected by inactivation of B2M. For this, a GFP-expressing VV was used in a standard plaque assay in the HeLa B2M KO cells. At 24 hours after infection, there was a reduction of 60% approximately in the number of plaques (Fig 6A). In addition, plaque size was clearly diminished (Fig 6B). Overall, these results indicate that VV replication was being negatively affected by B2M inactivation.

**Effect of B2M deficiency on virus entry**

We next investigated the stage of the replication cycle which was being affected in B2M KO cells. We anticipated an effect on an early step in the infection cycle, since viruses restricted to the early phase of the cycle (such as the D4-deficient virus) result in complete cell death (not shown). We therefore hypothesized that a block before that stage would be required for cell survival in the screen. Consequently, we focused on the virus entry process. We used an assay based on early luciferase expression [58], where an evaluation of the viral entry can be assessed by the luciferase activity, which is expressed under an early promoter and therefore, immediately after entry. Virus entry was significantly reduced as a result of B2M inactivation, both in HeLa and HAP1 cells (Fig 6C and 6D), indicating that inhibition of infection occurs at an early stage in the virus cycle, before the start of DNA replication.

Given the reported role of ITGB1 in VV infection, it could be reasoned that B2M inactivation might result in a decrease in ITGB1 levels, which in turn would inhibit VV infection. However, an indication that this might not be the case was that inactivation of B2M was more inhibitory than that of ITGB1 in our experimental setup (Fig 6D). Also, since B2M is required for the transport of several membrane proteins from the ER to the plasma membrane, it could be argued that ITGB1 transport could be affected in the absence of B2M. To assess this
possibility, we performed immunofluorescence with anti-ITGB1 antibodies in HeLa B2M KO cells (S4A Fig). Notably, ITGB1 plasma membrane levels in B2M KO cells were similar to that in parental HeLa cells, indicating that ITGB1 was transported efficiently to the plasma membrane independently of B2M. Therefore, we concluded that B2M KO effect on VV infection is not mediated by a decrease of ITGB1 in the cell surface.

An additional screening hit, AXL, has also been implicated in VV internalization [8,12,32,59]. However, we do not consider likely that the B2M effect on virus entry is mediated by AXL absence, since HAP1 cells do not express AXL [60]. This result was confirmed by Western blot, where the expression of AXL was detected in HeLa but not HAP1 cells (S4B Fig). This result is in agreement with AXL being an enhancer, albeit not an essential factor for infection [8,61].

VV produces different virus forms that differ in the number of membranes. In contrast with the prototypical intracellular mature virus (denoted IMV or MV) both extracellular virus and virus mutants lacking A26 can enter cells by direct fusion at the cell membrane [62,63]. Notably, inhibition by B2M KO of both extracellular virus and A26 deficient virus was smaller than that of intracellular virus (Fig 6E–6G), suggesting that entry by the endosomal route was involved.

Fig 4. Screen hits related to the ITGB1/AXL activated AKT pathway. Genes in bold letters were hits in the screen analysis (MaGeCK or ScreenBEAM). Genes in light gray letters encode proteins with related functions that were not screen hits. Activation of AKT by ITGB1 signaling pathway results in actin cytoskeleton reorganization, leading to VV endocytosis. CMIP and AHR are new suggested players in the pathway (see main text).
Fig 5. Effect of B2M KO on VV replication. A) Analysis of cell lysates using anti-B2M antibody. B) Immunofluorescence images of HeLa and HeLa-B2M KO cells labelled with anti-B2M antibody. C) Virus production in HeLa and HeLa-B2M KO. Infected cell monolayers (m.o.i. = 0.05) were collected 30 h.p.i. and
**B2M inactivation does not affect VV binding but delays internalization**

In order to test if virus attachment was affected in B2M KO cells we performed a binding assay in HeLa B2M KO cells. To measure binding, purified VV particles incorporating a fluorescent protein fused to a virion protein constituent (VV A4-cherry) were incubated with cells and maintained at 4˚C to avoid virus internalization, and virus particles bound to cells were quantitated by confocal microscopy (Fig 7A and 7B). Results showed no significant differences between control and B2M KO cells indicating no correlation between B2M presence and VV attachment.

We next analyzed the effect of B2M absence on the efficiency of VV internalization. For this, after the initial virus adsorption period, cells were incubated at 37˚C to allow virus internalization and therefore, internalized virus particles were quantitated at different times (Fig 8A). We used V-A4-cherry (for total virus) and an antibody targeting the VV Intracellular Mature Virion surface protein A27 to detect those viral particles that were not internalized (Fig 8B). Virus internalization occurred progressively over time in HeLa cells, similarly to previous reports [9]. Comparison with HeLa cells deficient in B2M showed a consistent decrease in the internalization rate in B2M KO cells, an effect that was more pronounced at the intermediate tested times (Fig 8A). These results suggest that a delay in virus internalization exists as a result of B2M inactivation, although some virus particles are eventually able to reach the cell interior.

We also tested whether B2M deficiency inhibited virus-induced membrane fusion. To isolate this activity from the internalization process, we tested the cell-cell fusion activity of uninfected cells mediated by cell-bound virus particles (“fusion from without”). Both in HeLa and in HeLa B2M KO cells, massive cell fusion was triggered by low pH treatment, but had basal levels at neutral pH (Fig 9).

The fact that virus internalization was diminished and/or delayed in B2M-deficient cells does not preclude additional effects later in infection. To ensure that later steps in infection were normal, we inspected cells at 18 hours post-infection by transmission electron microscopy. The different VV morphogenetic forms, including immature and mature virus forms, as well as enveloped viruses were present in the cells indicating no differences in the virus morphogenetic pathways (S5 Fig).

**VV colocalization with B2M**

As the specific role of B2M in early VV infection is related with the early steps of infection, we tested the degree of colocalization of B2M and VV at cell membrane. Since viral entry is a sequential process in which different protein-protein interactions may occur over time [64,65], different time points were included in the experiment. After adsorption of fluorescent V-A4-cherry particles at 4˚C, cells were stained with antibodies specific for B2M and ITGB1. Confocal images of non-permeabilized cells revealed a partial colocalization of B2M and attached virus particles (Fig 10A). We found approximately 50% of VV particles colocalizing with B2M at 0, 15, 30, 45 and 60 min post infection (S6 Fig). To determine if these colocalization results were consistent, we estimated VV/ITGB1 colocalization, that has been described to occur, at least in HeLa cells at 0 min [6]. Our results showed that 38% of adsorbed VV particles colocalized with structures containing ITGB1. Also measured that 24% of B2M-positive...
structures were also labeled with ITGB1, and that 20% of ITGB1-positive structures were also labeled with B2M. Those results indicate only partial colocalization of the two proteins with each other, and with the infecting VV particle, and show a substantially differential pattern for B2M and ITGB1 (Fig 10B).

Finally, we wished to determine if B2M was able to block virus infection by interacting directly with the virus particle. For that, purified VV particles were incubated with soluble
B2M and then used for infection. In those experiments, no significant differences were found (S7 Fig). On the other hand, a blocking assay was also performed pretreating the cells with different concentrations of anti-B2M antibody, followed by VV infection but we did not observe any significant blocking activity (S8 Fig).

**Discussion**

**CRISPR/Cas9 genetic screen**

In this work, we have used CRISPR/Cas9 technology to perform a pooled, genome-scale loss-of-function screen with the aim of identifying cellular genes necessary for VV infection. From
the design of our screening, it should be noted that we are only testing the non-essential gene set, since after subjecting pooled KO cell population to six passages, the cells in which essential functions are inactivated are depleted from the pool. Likewise, an enrichment is observed for

**Fig 8. B2M gene inactivation affects VV internalization.** A) and B) HeLa and B2M KO cells were infected with VV-A4-cherry at m.o.i. = 4 during 1 h at 4°C to avoid internalization. Cells were incubated for different times at 37°C and non-permeabilized cells were stained with antibody to VV-A27 (green) to visualize cell surface virus particles. White arrow-heads mark internalized virions (only red in merged image) and yellow-empty arrow-heads indicate non-internalized virions (green or yellow). Cell nucleus was labeled in blue by Hoechst staining. Internalized virions were quantified for each time point showing significant differences between HeLa and B2M KO cell lines. p-values: **** < 0.0001, *** < 0.001, ** < 0.01, * < 0.05, ns > 0.05. Scale bars: 5 μm.

https://doi.org/10.1371/journal.ppat.1010800.g008
some KOs in genes that perform functions related to the control of cell proliferation and apoptosis. This observation is common in screens of cellular genes [47]. The experimental approach to the problem of identifying cellular factors by this strategy was complicated by the considerable versatility and adaptability of VV infection. In fact, in our initial experiments, all cells showed cytopathic effect and suffered cell death over time, regardless of the multiplicity of infection used in the experiment. Failure to obtain even a single surviving cell suggests that a single KO mutation is not enough to confer complete resistance in the cells. This could be due to a number of different reasons. A first explanation might be that the virus is able to enter...
the cell using different, non-overlapping molecular pathways. Second, even if there is partial resistance, it may be difficult to isolate a few resistant cells within a large cell population of virus-producing cells. Indeed, since the bulk of the cells would remain susceptible they would generate high loads of progeny virus that may overcharge and kill the partially resistant cells. In this respect, it has been shown that even inactivated virus can induce cell death [66]. In similar approaches, high multiplicities of infection resulted in the death of the whole cell population, a difficulty already reported by Luteijn et al. [32].

In view of these considerations, we modified the screening protocols to exert a gradual enrichment of partially resistant cells. Those modifications included infection with viruses that have decreased spread or limited replication, and adjusting the multiplicity of infection to modulate the selective pressure. The screening design was directed at maintaining a controlled selective pressure in the form of virus-induced cell death in the cultures during extended periods. Importantly, this may favor the enrichment of cells harboring gene-KOs leading to enhanced cell growth, as we have seen over extensive passage of uninfected samples. Therefore, enrichment in our experiments may stem from increased resistance to infection or from faster cell growth. This was taken into account when analyzing the possible hits in the screening by comparing sgRNA changes in infected and control uninfected cultures (Fig 2B).

We have observed that viruses blocked in DNA replication, such as the V-ΔD4 virus mutant, efficiently promote cell death even though replication cycle is not completed. This
indicates that cell survival is not possible after the early stage of virus infection is reached. Because our screening was based on cell survival, it is not surprising that it was preferentially directed to the cell entry process. Vaccinia virus and Poxviruses in general are known to have a complex entry process into host cells, where they first bind in an unspecific manner to extracellular matrix components such as glycosaminoglycans (GAGs) and laminin, followed by a more specific attachment step [4,6,65]. During this process, signal activation pathways are triggered in the cell, leading to the internalization of the virus through fluid phase uptake and - to a lesser extent - direct fusion at plasma membrane [7,12,58]. With our screen approach, we identified several potential gene candidates that may play a role in early stages of infection. Statistically significant hits like \textit{ITGB1} and \textit{AXL}, as well as some of their downstream pathway proteins such as Akt-pathway-related proteins, the small GTPases -RhoA, Rac1, Cdc42-, or actin cytoskeleton remodeling proteins [6,8,67–69] were obtained. Additional gene hits were also related to these pathways. For instance, c-Maf activating protein (CMIP) was one of the strongest hits and is thought to participate in several cellular processes, including integrin expression through c-Maf activation, actin cytoskeleton remodeling and the Akt route [49,50,70]. Another hit was AhR (\textit{AHR}), which is known to be bound to c-Maf [71,72]. We suggest that CMIP may have emerged as a hit in our screen due to the concurrence of the different actions where this protein is involved (Akt pathway, cytoskeleton, integrin expression….) [50,73,74]. Because CMIP is a poorly studied gene, it will be of interest to study its potential function in VV infection. Overall, this study contributes to expand the big picture of the likely cell—VV interactions during the first steps of infection.

\textbf{β2-microglobulin gene (B2M)}

Unexpectedly, B2M gene appeared as one of the strongest hits in the screen, implying B2M protein is an important player in VV infection. B2M is a molecular chaperone that is expressed in most mammalian cells and binds several protein ligands such as MHC-I, HFE or FcRn before their transport to the cell surface. We used different approaches to determine the role of B2M in VV infection. First, we found that B2M deficiency leads to a decrease in viral plaques, and a lower viral progeny titer. Second, B2M role is relevant during early infection stages, since early gene expression was clearly diminished (Fig 6). More precisely, we demonstrated that B2M absence does not affect VV binding but it does decrease internalization (Figs 7 and 8). Although internalization differences were around 25% between B2M KO and normal cells, these differences were much greater in early expression luciferase assays (around 70%). Several explanations may account for the difference: for instance, the existence of an unproductive internalization pathway in B2M KO cells, not leading to early transcription. Also, the internalization delay and defect in B2M KO cells may be indicative of the inefficacy of VV virions finding their signaling ligands at cell surface, therefore abrogating them to the unproductive pathway above mentioned.

\textit{ITGB1}, which has also been shown to be involved in VV entry, was also a significant hit in the screen. However, several results point to B2M as acting independently of \textit{ITGB1}. First, the effect of the inactivation of B2M in VV infection in HAP1 cells was stronger than that observed \textit{ITGB1} KO. Furthermore, depletion of B2M in the HAP1-\textit{ITGB1}-KO line also resulted in a clear reduction of VV infectivity. This result shows that in the absence of \textit{ITGB1} and \textit{AXL} (the latter not being expressed in HAP1 cells), B2M is still necessary for VV infection. Those results can be explained as B2M acting as a key player in alternative virus entry pathway.

Pathway Analysis of the data from screening experiments showed that Class I MHC mediated antigen processing & presentation pathway was the most enriched one, including many proteins related to the proteasome and ubiquitin system. In this respect, a screen using
Monkeypox virus also pointed to several enriched ubiquitin genes and other B2M-related genes, such as TAPBP and CALR [31]. The ubiquitin system has been extensively studied for its importance during infection, and its relationship to B2M is hence intriguing in view of our results.

At this point, there is no clear mechanism to account for B2M role during infection. B2M requirement for VV infection might be the result of a direct involvement of this protein in the entry process. However, given that B2M forms protein complexes with a number of membrane proteins, one interesting possibility is that one of those complexes might act as a VV receptor or internalization factor. Nonetheless, we have analyzed our screening results searching for these B2M related genes, and we found no clear results. Gene redundancies, in particular regarding HLA genes, may obscure the screening results, that have the limitations imposed by the fact that only single gene inactivations are tested. Current experiments are directed at exploring if any of those B2M heterocomplexes is indeed involved in virus entry.

The known function of B2M does not offer an evident link with a mechanism of virus entry. However, its function in the initial steps of VV infection is not a singular case. Intriguingly, some similarities exist with Coxsackievirus A9 (CAV9) -an enterovirus B- whose internalization is also mediated by B2M [75–77] and which also makes use of at least two subunits of integrin; beta 6 and beta 3. Furthermore, CAV9 entry is mediated by dynamin, as is also the case with VV [78]. Recently, it has been found that the effect of B2M for Enterovirus B entry can be explained by the need of B2M in mediating the transport to the membrane of its receptor, the Human Neonatal Fc Receptor (FcRn) [79,80]. Expanding the similarities to the case of CAV9, we obtained ASAP1 as a hit (S3 Table), a GTPase activating protein involved in Arf1, Arf5 and Arf6 activation and cytoskeleton remodeling [81], the latter of which being known to mediate endocytosis for some viruses, like CAV9 [76]. As authors suggested, virions might undergo an unproductive entry pathway in B2M absence [76], a hypothesis that is consistent with our results. Due to the several similarities in cellular requirements of CAV9 and VV entry, it is likely that one of the entry mechanisms for VV is shared by CAV9. In any event, more research is needed to further clarify the details of the process.

We have shown that B2M deficiency does not affect cell-cell fusion mediated by virus particles, an event that is triggered at low pH (Fig 9). Also, we found that the effect is predominantly directed at intracellular virus forms, that are known to require low pH for membrane fusion. In contrast, extracellular virus and A26-deficient virus, which can induce membrane fusion at neutral pH and can enter cells directly at the cell membrane, were not affected by B2M inactivation (Fig 6). Those observations are consistent with a requirement of B2M in the internalization of incoming virus particles. The possible involvement of B2M in activating the signals leading to macropinocytosis will require further investigation.

One last interesting aspect of B2M involvement in virus entry is the relevance of B2M product (β-2 Microglobulin) in the immune response. The involvement of B2M as a pro-viral factor might have multiple consequences regarding the pathogenesis and immune response in animal infection. Interestingly, two reports in the literature found that B2M-deficient mice were remarkably resistant to VV infection, despite the lack of cell-mediated immunity in those animals as a consequence of MHC-I deficiency [56,57]. This result suggests the B2M deficiency has also a VV blocking effect, even though those mice have a T cell immunodeficiency.

Overall, this report adds a new player to our picture of the complex interplay between cell and virus in the VV entry process. Delineation of the protein interactions and pathway activations taking place in this process will undoubtedly involve multiple players yet to be discovered.
Materials and methods

Cells

HeLa (ATCC CCL-2) cells were grown in Eagle’s Minimal Essential Medium (EMEM) containing 7% fetal bovine serum (FBS). BSC-1 cells (ATCC CCL-26) were grown in Eagle’s Minimal Essential Medium (EMEM) with 5% fetal bovine serum (FBS). HAP1 and its derived lines (B2M KO, ITGB1 KO and double B2M/ITGB1 KO (DKO) were purchased from Horizon Discovery and were grown in Iscove’s Modified Dulbecco’s Medium (IMDM) containing 7% fetal bovine serum (FBS). HEK-293T cells were grown in Dulbecco’s Minimal Essential Medium (DMEM) with 7% fetal bovine serum (FBS). All media were supplemented with 0.1 mg/mL penicillin, 0.1 mg/mL streptomycin, 2 mM L-glutamine (BioWhittaker). Cells were grown in a 5% CO₂ incubator at 37°C.

Viruses

Vaccinia virus (VV) Western Reserve (WR) strain was obtained from the American Type Culture Collection (ATCC VR-119) and routinely propagated in BSC-1 cells. Previously described viruses V-GFP (recombinant WR expressing GFP) [82], and V-ΔA27ΔF13 (recombinant having the A27L and F13L genes deleted) are already described [41].

Virus infections were performed in media containing 2% FBS. Viral titers in cell lysates obtained after disrupting the cells by three rounds of freeze/thawing were determined by the standard VV plaque assay in BSC-1 cells [83].

Isolation D4R expressing cells

Complementing cell lines 293-D4rR and Helo-D4rR were obtained by inserting the VV D4R gene in the genome of the parental cells using the Flp-in T-Rex system from Invitrogen. The integrative plasmid pCDNA-FRT-TO-D4R was transfected in the cell line HeLa Flp-In T-Rex (R71407) or 293-FITR- Flp-In T-Rex (R78007) and subsequently cell clones were selected for hygromycin resistance. A bicistronic construct was inserted, placing the VV D4R gene downstream of a tetracyclin-inducible promoter and the TagRFP gene downstream of an IRES sequence. Clones generated from 293 and HeLa were chosen by monitoring the appearance of red fluorescence after tetracycline induction. The efficacy of cell line complementation was tested by plaque phenotyping with the V-ΔD4L virus.

Generation of recombinant and mutant Vaccinia viruses

Recombinant virus V-A4-cherry was generated as previously described [78]. Briefly, BSC-1 cells (6-well plate format, 10⁶ cells/well), were infected at a multiplicity of infection (m.o.i.) of 0.05 PFU/cell with virus WR. After 1 h viral adsorption, virus inoculum was removed and cells were then transfected with 2 μg of plasmid pm-cherry-A4L (kindly provided by Wen Chang) using FuGeneHD (Promega) according to the manufacturer’s recommendations. After 2 to 3 days, cells were harvested, and recombinant virus was isolated by three consecutive rounds of plaque purification. Viral stocks were generated in BSC-1 cells and viral titers were determined by standard plaque assay (PFU/mL).

V-ΔD4 virus was isolated following the protocol already described [43,44] by infection/transfection of BSC-1 cells with WR virus and plasmid pΔD4R-dsRed. pΔD4R-dsRed contains the dsRed gene downstream of a synthetic early/late promoter between two DNA segments acting as recombination flanks for the D4L locus. At 72h the culture was collected and several successive rounds of plaque purifications in BSC-1 cells were performed by selecting large red plaques (representing single recombinants). The resulting virus was amplified in the
complementing cell line expressing the D4R gene (HeLa-D4R). The amplified stock was plaque purified in the HeLa-D4R line. The size phenotype for each clone was checked by plating in parallel in the BSC-1 line and the HeLa-D4L line. Virus clones that produced large plaques in the HeLa-D4 cell line and single infected cells in BSC-1 were selected.

V-e.Luc VV recombinant expressing firefly luciferase (Renilla reniformis) under the control of an early promoter was constructed by inserting an early-Luc cassette in plasmid pA-E-Luc into the A27L locus using a plaque selection procedure [41]. Recombinant VV expressing nanoLuc (V-e-nLuc) from an early promoter has been previously described [41]. An A26-deficient VV expressing nanoLuc was isolated as follows. Plasmid pA-E-nLuc, in which the flanking sequences at the A27L locus correspond to 400 nucleotides at the end of the A25L gene and 400 nucleotides at the beginning of the A26L gene [41], was digested with BamHI and NheI enzymes and subsequently religated to obtain plasmid pA-E-nLuc-A26-. By this procedure, approximately 200 nucleotides were removed from the A26L sequence. It was used into the A27L locus using a plaque selection procedure [41].

**Lentiviruses**

Lentivirus stocks production were obtained by cotransfection of HEK293T cells with the lentiviral plasmid with the packaging plasmid psPAX2 and pseudotyping plasmid pCMV-VSV-G. Plasmid psPAX2 was a gift from Didier Trono (Addgene plasmid # 12260; http://n2t.net/ addgene:12260; RRID:Addgene_12260). pCMV-VSV-G was a gift from Bob Weinberg (Addgene plasmid # 8454; http://n2t.net/addgene:8454; RRID:Addgene_8454). For sgRNA expression, plasmids lentiGuide-Puro (Addgene plasmid # 52963; http://n2t.net/ addgene:52963; RRID:Addgene_52963) or lentiCRISPR v2, (Addgene plasmid # 52961; http:// n2t.net/addgene:52961; RRID:Addgene_52961) provided from Feng Zhang, were used. For stock titer determination, HeLa cells on MW6 plates were infected with successive dilutions of the lentiviral particle stock and incubated with the corresponding selective medium (blasticidin 5 μg/mL or puromycin 1 μg/mL). After cell clones were visible at the microscope, titer was calculated from the number of resistant clones.

**Cell-Cell fusion assay**

Cell fusion was performed by mixing HeLa cells stably expressing fluorescent proteins obtained by lentiviral transduction. To obtain HeLa cells lines stably expressing GFP, lentiviral stocks were derived from plasmid pRRL.sin18.CMV-eGFP, derived from the pRRLsin18.CMV.eGFPWpre series [84–86] was kindly provided by Juan Carlos Ramirez.

To obtain a lentiviral plasmid for mScarlet fluorescent protein expression, the Scarlet coding sequence was PCR amplified from plasmid pRB-mScarlet [87] using oligonucleotides lentiScarlet5': CCGTCTAGAGGATCCACCATGCGTACGAAGGGCGAGGAGGAGCAGTGACTACAGGAG and LentiScarlet3': CGCGAATTCTTCGAAACTAATTGTACAGCTCCGTCAATGCGCCGCGCCCGGT, subsequently digested with XbaI and EcoRI and inserted into the backbone of lentiviral plasmid LentiCas9-Blast, digested with XbaI and EcoRI to remove the coding sequence of the Cas9-Blasticidin cassette.

**Isolation of Cas9 expressing HeLa cells**

LentiCas9-Blast plasmid was a gift from Feng Zhang and was obtained from Addgene (Addgene plasmid # 52962; http://n2t.net/addgene:52962; RRID: Addgene_52962) [33]. HeLa cells grown on MW6 wells were transduced with different dilutions of a lentiviral stock obtained from LentiCas9-Blast. After applying selection with blasticidin (5 μg/mL) for 10 days,
cell clones were visible at certain dilutions from which lentiviral titers were estimated. Cells transduced with an m.o.i. of 3–5 were cloned by limit dilution in MW96 wells and individual clones were harvested and expanded for further analysis. Cas9 expression was verified by immunofluorescence and western blotting using anti-flag antibody. A cell clone with the highest Cas9 expression was termed HeLa-Cas-ML, expanded and used for subsequent experiments.

HeLa and B2M KO cell lines stably expressing GFP and Scarlet were obtained by transduction with lentiviral stocks obtained from pRRL.sin18.CMV-eGFP or pLenti-Scarlet with titers of 5x10^6 and 8x10^6 respectively. After transduction and 3-day subculture, cultures showed approximately 70% fluorescence-positive cells. Fluorescent cells were separated by flow cytometry in a FACSaria II (Becton Dickinson) cell sorter. Settings were 488 nm laser: 530/30-nm emission for GFP-positive cells and 488 nm laser: 610/20-nm emission for Scarlet-positive cells.

**CRISPR Knock-Out (GeCKO) v2.0 libraries: lentivirus stock and derived cell lines**

The Human GeCKO v2.0 library, a gift from Feng Zhang, in the two lentiviral vector version (Addgene 1000000049), was used [33,34]. The lentiviral library LentiGuide-puro consists of specific sgRNA sequences for gene knock-out covering the gene set of the human genome. The library is supplied as two half-libraries (A and B). When combined, the libraries contain 6 sgRNAs per gene (3 sgRNAs in each library).

HeLa-Cas-ML cells were transduced with lentiviral libraries A and B separately and selected with puromycin to obtain a cell mixture called HeLa-Mix. For each library, cells in 4 subconfluent T150 flasks were transduced with approximately 2 x 10^7 lentiviral particles. At 24 h, medium was replaced by fresh medium containing 1 μg/mL puromycin. After three days the cells were harvested, pooled, and subcultured to 8 T225 flasks. Subsequently, cells were transferred to 24 T225 flasks maintaining the selective medium at all times for 10 days and constituting the pass 0.

**Genetic screen**

GeCKO KO cell pools in 2 T225 flasks (about 10^8 cells) were infected in each condition. Cells were maintained in EMEM-7% FBS except during virus adsorption, which was carried out in EMEM containing 2% FBS. Uninfected control cells were maintained in culture for 8 subcultures before analysis. Detached cells from the infected cultures were removed regularly. Infection was monitored by detecting infected cells by fluorescence (red fluorescence for V-ΔD4L and blue fluorescence for V-ΔA27ΔF13). To exert selective pressure in the cultures in the form of VV infection, cells were occasionally re-infected with fresh inoculum. If cultures reached confluence, they were subcultured into new T225 flasks. To avoid population bottlenecks in the sgRNA population, cell dilutions at each passage were never greater than 4-fold. The last passage was allowed to reach confluence and the cells were harvested and prepared for sgRNA quantitation in the surviving population. The conditions under which the infection experiments were performed are summarized in S1 Table.

After the selective process, cellular DNA was extracted and the lentiviral region containing the sgRNA sequence was PCR amplified and sequenced. For DNA purification cell samples were suspended in 500 μL of lysis buffer (10 mM Tris (pH 8.0), 10 mM EDTA, 10% SDS and 100 μg/mL proteinase K) and incubated 3 h at 55˚C or o/n at 50˚C. Samples were then extracted with an equal volume of phenol twice, then 3–5 times with a volume of phenol: chloroform: isoamyl alcohol (25: 24: 1) and finally once with a volume of chloroform: isoamyl alcohol.
alcohol (24:1). DNA was then precipitated by adding one-tenth volume of 3 M sodium acetate and two volumes of ethanol and, cooled to -20°C for 1 h followed by 30 min centrifugation at 4°C and 13000 rpm. The pellet was resuspended in 300 μL TE with RNAase mix and frozen at -20°C for storage. Amplicon for sequencing was derived from cellular DNA by three successive nested PCRs. PCR reactions were performed with Biotools thermostable DNApol enzyme. The first PCR was performed on all the purified DNA as template, by setting up multiple reactions containing each 5 μg of DNA in 100 μL of reaction volume, with 5’P1, 3’P1 oligonucleotides and 15 amplification cycles. After the first PCR, all reactions were pooled and a second PCR was performed in four-fold less reactions with a 1:20 dilution of the first as template in 100 μL of reaction with oligonucleotides 5’P2, 3’P2, and 20 amplification cycles. The third PCR was performed similarly (1:20 template, 1:4 number of reactions, 20 cycles) to incorporate the sequences and the barcodes necessary for Illumina sequencing. Each sample carries a different combination of R and F oligonucleotides in order to multiplex the Illumina sequencing run. Sample libraries were equimolarly mixed and the resulting pools quantified by dsDNA fluorescence (QuantiFluor, Promega) and qPCR (KAPA Library Quantification kit, Roche). Single-end sequencing (76 bases) was performed in a NextSeq 500 (Illumina) sequencer or in a Hiseq (Illumina).

**Statistical analysis and screen data analysis**

Control and infected samples read counts were analyzed with MaGeCK test function [45] and ScreenBEAM algorithm [48]. MaGeCK log2-fold change (LFC) scores of each gene were calculated by comparing the endpoint of each experiment with the initial cell population, and used for data visualization using R coding language. A cutoff of FDR < 0.05 was applied for the heatmap representation to select the best hits of each screen experiment. For ScreenBEAM analysis, the 20 best hits were selected from each experiment following z-score criteria. Genes with less than 3 successful sgRNAs as well as gene knockouts enriched in control were filtered out. ReactomePA (R package) was performed using the top 1% gene list from MaGeCK output. Statistical analyses were performed using Student’s t test and one-way ANOVA (when more than two group comparisons) using Bonferroni correction method (GraphPad Prism 8 and RStudio 1.2.5033).

**Isolation of KO cell clones**

HeLa B2M KO lines: To obtain a B2M KO cell line, pLentiCRISPRv2 was digested with BsmBI, and a pair of annealed oligonucleotides were cloned into the single guide RNA cloning site. Two different sgRNAs for human B2M gene were selected. Oligonucleotides for clone 1 were: B2M_sg1f CACCGACTCACGTGGATAGCCTCC and B2M_sg1r AAACGGAGGCTATCCAGCGTCTCC and B2M_sg1r AACCAGGAGCCTATCCAGCGTCTCC. Oligonucleotides for clone 2 were: B2M_sg2f CACCGACTCACGTGGATAGCCTCC and B2M_sg2r AAACGGAGGCTATCCAGCGTCTCC. Oligonucleotides for clone 2 were: B2M_sg2f CACCGACTCACGTGGATAGCCTCC and B2M_sg2r AAACGGAGGCTATCCAGCGTCTCC. Lentiviral plasmids containing B2M sgRNA were obtained by cloning the hybridized oligonucleotide pairs B2M_sg1f/B2M_sg1r and B2M_sg2f/B2M_sg2r to obtain plasmids pLentiCRISPRv2-B2M1 and LentiCRISPRv2-B2M2 respectively. HeLa cells were transduced with lentiviral preparations of LentiCRISPRv2-B2M1 or LentiCRISPRv2-B2M2 and puromycin resistant clones were selected. After western blotting analysis, clones that did not express B2M were selected, expanded and verified by sequencing the genomic target region [88].

**VV entry and blocking assays**

For VV entry assays, luciferase activity driven from a VV early promoter at 3 h.p.i. was measured. Cells were plated in MW96 wells and incubated with V-e.luc (m.o.i. = 0.8) for 1 h for
adsorption. Cells were washed with PBS and incubated for two additional hours at 37˚C with media free of phenol red. Cells were lysed using ONE-Glo EX Luciferase Assay System (Promega) and luciferase activity was measured using EnSight Multimode Plate Reader (PerkinElmer). Blocking assays were performed as follows: for antibody blocking assay HeLa cells were incubated with two different concentrations of anti-B2M antibody (5 and 15 μg/mL) or anti-caveolin antibody (15 μg/mL) -used as negative control- 1 h at room temperature. Subsequently, the cells were infected with V-e.luc (m.o.i. = 0.8) for 1 h and then washed with fresh medium. After 3 h.p.i., cells were lysed and luciferase activity was measured. For B2M blocking assay, V-e.luc inoculum was incubated with growing concentrations of soluble BSA (control) or 30 μg/mL B2M for 1 h at room temperature. Then, HeLa cells were incubated with the pretreated inoculum for 1h and finally washed with fresh medium. At 3 h.p.i. cell extracts were prepared and subsequently luciferase activity was measured.

Cell-cell fusion assays induced by VV particles (fusion from without).

Cell-cell fusion assays induced by VV particles were performed as previously described [62,89]. Briefly, HeLa cells and B2M KO cells expressing red fluorescent protein (RFP) or green fluorescent protein (GFP) were mixed at a ratio of 1:1 and seeded into 96-well plates. 18 hours later, cells were pretreated with 40 μg/ml cordycepin (Sigma) for 60 min and subsequently incubated with wild-type (WT) WR at a m.o.i. of 100 PFU per cell in triplicate. Cordycepin was maintained in the medium throughout the experiment. After 50 min virus adsorption, cells were treated with PBS at either pH 7.4 or pH 5.0 at 37˚C for 3 min, washed with growth medium, further incubated for 2h at 37˚C, fixed in 4% paraformaldehyde and incubated with a solution of Hoechst 2 mg/mL. Cell fusion was quantitated by counting more than 600 nuclei from multiple images. Percentages of cell fusion were calculated as follows: (nuclei in fused cells/ total number of nuclei) × 100. Fusion assays were repeated three times and statistical analyses were performed using Student’s t test in Prism (version 8) software (GraphPad).

Immunofluorescence microscopy

Cells were seeded in round glass coverslips, washed with PBS, fixed with ice-cold 4% paraformaldehyde for 12 min and permeabilized in PBS containing 0.1% Triton X-100 for 15 min at room-temperature. Cells were treated with PBS containing 0.1 M glycine for 5 min and incubated with primary antibodies in PBS-20% FBS for 30 min, followed by incubation with secondary antibodies diluted 1:300 in PBS-20% FBS.

To detect virus particles by antibody labeling on the cell surface, immunofluorescence was carried out on non-permeabilized cells treated as follows: cells were seeded in coverslips, washed and incubated at 12˚C for 1 h with primary antibodies in PBS-20% FBS followed by incubation at 12˚C for 1 h with secondary antibodies in PBS-20% FBS. Subsequently, cells were fixed by ice-cold 4% paraformaldehyde for 12 min and treated with PBS containing 0.1 M glycine for 5 min. Quantitation was derived from counting virus particles in 20–30 cells per sample.

Antibodies used were: Rabbit monoclonal anti-beta 2 Microglobulin EP2978Y antibody (abcam, ref ab75853) diluted 1:300; Mouse monoclonal anti-Integrin beta 1 [12G10] antibody (abcam, ref ab30394) diluted 1:70; Mouse monoclonal anti-VAC (WR) A27L (Beiresources, ref: NR-569) diluted 1:250; anti-mouse IgG-Alexa Fluor 488, anti-mouse IgG-Alexa Fluor 594, anti-rabbit IgG-Alexa Fluor 488 antibodies (Invitrogen) diluted 1:300. Mouse monoclonal anti-Flag 1:500 (Sigma F1804).

For DNA staining, cells in glass coverslips were incubated with 2 mg/mL bisbenzimide (Hoechst dye. Sigma) for 30 min. Cell surface staining was performed by incubation with 0.02
mg/mL wheat germ agglutinin (WGA)-Alexa488 (ThermoFisher Scientific) incubation at concentration for 30 min at 12°C.

For internalization assay, cells were seeded in coverslips, and V-A4-cherry (m.o.i. = 4) was incubated 1 h at 4°C to allow viral adsorption. Cells were then incubated at 37°C for different times in a 5% CO₂ incubator to allow internalization. Cells were washed three times with PBS and incubated with antibodies following the non-permeabilization method described above.

Binding assays were based on protocols described elsewhere [6,20,90,91]. Briefly, cells grown in coverslips were infected with V-A4-cherry for 1 h at 4°C (m.o.i. = 30), washed with ice-cold PBS and fixated with paraformaldehyde 4% for 12 min at 4°C. Cells were treated with PBS containing 0.1 M glycine for 5 min and incubated 30 min with 0.02 mg/mL Wheat Germ Agglutinin-Alexa488 diluted in PBS-20% FBS. Cells were washed with PBS, mounted with FluorSave reagent (Millipore), observed by fluorescence microscopy and counted manually. 20–30 cells were counted, with an average of 2–3 cells per field.

Western blotting

Whole cell lysates were prepared in denaturant buffer (80 mM Tris-HCl, pH 6.8, 2% sodium dodecyl sulfate [SDS], 10% glycerol, 0.01% bromphenol blue solution and 0.71 M 2-mercaptoethanol). After SDS-polyacrylamide gel electrophoresis (PAGE), proteins were transferred to PVDF membranes and incubated 1 h at RT with primary antibody in PBS containing 0.05% Tween-20 and 1% nonfat dry milk. Primary antibodies were Rabbit monoclonal anti-beta 2 Microglobulin EP2978Y antibody (abcam, ref ab75853) diluted 1:100; Rabbit monoclonal anti-Axl C89E7 antibody (Cell Signaling Technology, ref 8661) diluted 1:1000; Rabbit polyclonal anti-beta Actin antibody (GeneTex, ref GTX109639) diluted 1:1000 and Mouse monoclonal anti-Flag 1:1000 (Sigma F1804). After extensive washing with PBS-0.05% Tween-20, membranes were incubated with HRP-conjugated secondary antibodies diluted 1:3000. Secondary antibodies were polyclonal goat anti-rabbit IgG (Dako P0448), and anti-mouse polyvalent immunoglobulins (Sigma, ref: A0412). After removal of unbound antibody, membranes were incubated for 1 min with a 1:1 mix of solution A (2.5 mM luminol [Sigma], 0.4 mM p-coumaric acid [Sigma], 100 mM Tris-HCl, pH 8.5) and solution B (0.018% H₂O₂, 100 mM Tris-HCl, pH 8.5) to finally record the luminescence using a Molecular Imager Chemi Doc-XRS (Bio-Rad).

Electron microscopy

For ultrastructural analysis, HeLa and HeLa B2M KO cells grown on 12 mm glass coverslips, and infected with VV for 18h were fixed with a mixture of 2.5% glutaraldehyde and 2% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) for 1 h at RT. Cells were washed twice at 4°C with phosphate buffer; postfixation was performed with a mixture of 1% osmium tetroxide, 1% potassium ferricyanide in water for 1 h at 4°C and afterwards 0.15% tannic acid for 1 min at RT. Samples were treated with 1% uranyl acetate for 1 h at RT and dehydrated in increasing concentrations of ethanol (50, 75 and 95%) for 10 min each; and 100% ethanol three times for 30 min each, at 4°C. Infiltration in epoxy-resin was done at RT using increasing concentrations of resin (50 and 100%) and polymerization was performed at 60°C for 3 days. Ultrathin sections of the samples were stained following standard procedures with 4% aqueous uranyl acetate and 2% lead citrate. Sections were imaged on a FEI Tecnai 12 electron microscope operated at 120 kV and equipped with a FEI Ceta CCD camera.

Supporting information

S1 Fig. Screening experiment example. A representative hit analysis for one of the 27 screen experiments analyzed with MaGeCK (exp 1_1). A) Hits with FDR < 0.05, and LFC > 0 for
infected experiments or LFC < 0 for uninfected are labelled. Best hits are those who have the
greatest LFC in infected control and the lowest LFC in control experiment (uninfected). B)
Volcano-like plot representing each gene KO according to their FDR (y axis) and LFC (x axis).
(TIF)

S2 Fig. Clustermap of results from all experimental conditions. A clustering algorithm
(Pearson correlation) was used to analyze the screen hits and experiments. Data was the gene
rank considering the final hits list. Different rounds of reinfection and the different m.o.i.
applied are indicated as red boxes. The VV mutant used in each experiment is indicated as
black or white circles for V-ΔA27ΔF13 and V-ΔD4L, respectively.
(TIF)

S3 Fig. Mutations in B2M KO cell clones. Sanger sequencing of the CRISPR/Cas9-targeted
regions of both HeLa B2M KO clones compared to WT (HeLa), followed by Synthego ICE
software analysis. Resulting INDEL-mutations disrupt B2M ORF at genomic level.
(TIF)

S4 Fig. Additional characterization of B2M KO cells. A) Immunofluorescence images of
HeLa and HeLa B2M KO cells stained with anti-ITGB1 antibody. Scale bars: 20 μm. B) Western
blot of whole cell lysates of HAP1 and HeLa cells, showing HAP1 cells do not express AXL
protein.
(TIF)

S5 Fig. Electron microscopy of VV-infected HeLa B2M KO cells. Cells infected for 18h were
fixed and processed for electron microscopy. Note the presence of Immature virus particles
(black arrowheads), Mature virus (white arrowheads) or enveloped virus (white arrows).
(TIF)

S6 Fig. VV / B2M colocalization rates. HeLa cells were infected with V-A4-cherry (red) at an
m.o.i. of 5 PFU/cell for 1 h at 4˚C and unbound virus was removed by washing. Non-permea-
bilized cells were then incubated for different times at 37˚C and stained with anti-B2M to ana-
lyze colocalization.
(TIF)

S7 Fig. Blocking assay for VV entry by soluble B2M. V-e.Luc virus was incubated with
increasing concentrations of soluble BSA (control) or B2M (0, 5, 15, 30 and 50 μg/mL) protein
for 1 h at room temperature. Then, HeLa cells were incubated for 1 h with the pre-treated
inoculum. At 3 h.p.i. luciferase activity was determined as a measure of viral entry and early
gene expression. No significant differences were found. p-values: **** < 0.0001, *** < 0.001, **
< 0.01, * < 0.05, ns > 0.05.
(TIF)

S8 Fig. Blocking assay for VV entry with anti-B2M antibody. HeLa cells were incubated
with two different concentrations of anti-B2M antibody (5 and 15 μg/mL) for 1 h at room tem-
perature. Anti-caveolin antibody (15 μg/mL) was used as negative control. After antibody
treatment, HeLa cells were infected with V-e.Luc (m.o.i. 0.8), and eventually 3 h.p.i. luciferase
activity was determined as a measure of viral entry and early gene expression. No significant
differences were found. ns, not significant (p > 0.05).
(TIF)

S1 Table. Screen_conditions. Different screen experiments were performed. Experiments are
summarized where each mutant, m.o.i. and number of reinfections are shown.
(XLSX)
S2 Table. Screen Results. Gene summary files obtained from MaGeCK test showing the FDR and LFC for each gene in each experiment. (XLSX)

S3 Table. ScreenBEAMresults. Summary of ScreenBEAM results showing good guides ("pass filter"), B-score, z-score, p-value, FDR and standard deviations for each gene, where x is for control experiment and y for infected experiment. Top 20 genes were selected as hits. (XLSX)

S4 Table. Reactome_Pathway analysis. Results from Reactome Pathway analysis. The most enriched pathways are shown in descendent order. Statistical data is shown (i.e. pvalue, p. adjust), as well as the genes ID that belong to each enriched pathway. (XLSX)

Acknowledgments
We are grateful to Dr. Wen Chang for plasmid pm-cherry-A4L, and Jerson Garita-Cambrónero for assistance with computer analysis. We wish to thank Carmen Terrón and Daniel Luque for excellent electron microscopy and Carmen Hernando for sorting. Our gratitude to Dr. Feng Zhang for making the CRISPR/Cas human pooled libraries available through Addgene. We want to thank Marco Y. Hein for critical reading of the manuscript.

Author Contributions
Conceptualization: Alejandro Matía, Maria M. Lorenzo, Rafael Blasco.
Data curation: Alejandro Matía, Rafael Blasco.
Formal analysis: Alejandro Matía, Rafael Blasco.
Funding acquisition: Rafael Blasco.
Investigation: Alejandro Matía, Maria M. Lorenzo, Yolimar C. Romero-Estremera, Juana M. Sánchez-Puig.
Methodology: Alejandro Matía, Angel Zaballos.
Project administration: Rafael Blasco.
Resources: Alejandro Matía, Maria M. Lorenzo, Juana M. Sánchez-Puig, Rafael Blasco.
Supervision: Maria M. Lorenzo, Rafael Blasco.
Validation: Angel Zaballos.
Visualization: Alejandro Matía, Maria M. Lorenzo, Rafael Blasco.
Writing – original draft: Alejandro Matía, Maria M. Lorenzo, Rafael Blasco.
Writing – review & editing: Angel Zaballos, Rafael Blasco.

References
1. Moss B. Poxviriidae: the viruses and their replication. Fields Virology. 2007; 2:2905–46.
2. Howley PM, Knipe DM. Fields virology. 7th ed. Philadelphia: Wolters Kluwer; 2020.
3. Schmidt FI, Bleck CK, Mercer J. Poxvirus host cell entry. Curr Opin Virol. 2012; 2(1):20–7. https://doi.org/10.1016/j.coviro.2011.11.007 PMID: 22440962
26. Wei J, Alfajaro MM, DeWeirdt PC, Hanna RE, Lu-Culligan WJ, Cai WL, et al. Genome-wide CRISPR

25. Zhu Y, Feng F, Hu G, Wang Y, Yu Y, Zhu Y, et al. A genome-wide CRISPR screen identifies host fac-

24. Li Y, Muffat J, Omer Javed A, Keys HR, Lungjangwa T, Bosch I, et al. Genome-wide CRISPR screen

23. Li B, Clohisey SM, Chia BS, Wang B, Cui A, Eisenhaure T, et al. Genome-wide CRISPR screen identi-

22. Ma H, Deng Y, Wu Y, Jia G, Anaya E, Zhang J, et al. A CRISPR-Based Screen identifies Genes Essential

21. Mercer J, Helenius A. Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells. Proc Natl Acad Sci U S A. 2010; 107(20):9346–51. https://doi.org/10.1073/pnas.1004618107 PMID: 20439710

20. Locker JK, Kuehn A, Schleich S, Rutter G, Hohenberg H, Wepf R, et al. Entry of the two infectious

19. Rizopoulos Z, Balisteri G, Kilcher S, Martin CK, Syedbash A, Helenius A, et al. Vaccinia Virus Infec-

18. Bengali Z, Satheshkumar PS, Moss B. Orthopoxvirus species and strain differences in cell entry. Virology. 2005. 09.037 PMID: 16364735

17. Mercer J, Knebel S, Schmidt FI, Crouse J, Burkard C, Helenius A. Vaccinia virus strains use distinct

16. Bengali Z, Townsley AC, Moss B. Vaccinia virus strain differences in cell attachment and entry. Virology. 2009; 389(1–2):132–40. https://doi.org/10.1016/j.virology.2009.04.012 PMID: 19428041

15. Bongianni H, Chiu WL, Lin CL, Yang MH, Tzou DL, Chang W. Vaccinia virus 4c (A26L) protein on intracellular mature virus binds to the extracellular matrix laminin. J Virol. 2007; 81(5):2149–57. https://doi.org/10.1128/JVI.02302-06 PMID: 17166913

14. Moss B. Membrane fusion during poxvirus entry. Semin Cell Dev Biol. 2016; 60:89–96. https://doi.org/10.1016/j.semcdb.2016.07.015 PMID: 27423915

13. Bengali Z, Townsley AC, Moss B. Vaccinia Extracellular Virions Enter Cells by Macropinocytosis and Acid-Activated Membrane Rupture. EMBO J. 2011; 30(17):3647–61. https://doi.org/10.1038/emboj.2011.245 PMID: 21792173

12. Mercer J, Helenius A. Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells. Science. 2008; 320(5875):531–5. https://doi.org/10.1126/science.1155164 PMID: 18436786

11. Mercer J, Helenius A. Apoptotic mimicry: phosphatidylserine-mediated macropinocytosis of vaccinia virus. Ann N Y Acad Sci. 2010; 1209:49–55. https://doi.org/10.1111/j.1749-6632.2010.05772.x PMID: 20958316

10. Schmidt Fl, Bleck CK, Helenius A, Mercer J. Vaccinia extracellular virions enter cells by macropinocytosis and acid-activated membrane rupture. EMBO J. 2011; 30(17):3647–61. https://doi.org/10.1038/emboj.2011.245 PMID: 21792173

9. Zhu Y, Feng F, Hu G, Wang Y, Yu Y, Zhu Y, et al. A genome-wide CRISPR screen identifies host fac-

8. Morizono K, Xie Y, Olafsen T, Lee B, Dasgupta A, Wu AM, et al. The soluble serum protein Gas6 bridges virion envelope phosphatidylserine to the TAM receptor tyrosine kinase Axl to mediate viral entry. Cell Host Microbe. 2011; 9(4):286–98. https://doi.org/10.1016/j.chom.2011.03.012 PMID: 21501828

7. Hiley CT, Chard LS, Gangaswaran R, Tysome JR, Briat A, Lemoine NR, et al. Vascular endothelial growth factor A promotes vaccinia virus entry into host cells through activation of the Akt pathway. J Virol. 2013; 87(5):2781–90. https://doi.org/10.1128/JVI.00854-12 PMID: 23269798

6. Izmailyan R, Hsao JC, Chung CS, Chen CH, Hsu PW, Liao CL, et al. Integrin beta1 mediates vaccinia virus entry through activation of PI3K/Akt signaling. J Virol. 2012; 86(12):6677–87.

5. Chiu WL, Lin CL, Yang MH, Tzou DL, Chang W. Vaccinia virus 4c (A26L) protein on intracellular mature virus binds to the extracellular matrix laminin. J Virol. 2007; 81(5):2149–57. https://doi.org/10.1128/JVI.02302-06 PMID: 17166913

4. Moss B. Poxvirus entry and membrane fusion. Virology. 2006; 344(1):48–54. https://doi.org/10.1016/j.virol.2005.09.037 PMID: 16364735

3. Moss B. Poxvirus entry and membrane fusion. Virology. 2006; 344(1):48–54. https://doi.org/10.1016/j.virol.2005.09.037 PMID: 16364735

2. Moss B. Membrane fusion during poxvirus entry. Semin Cell Dev Biol. 2016; 60:89–96. https://doi.org/10.1016/j.semcdb.2016.07.015 PMID: 27423915

1. Moss B. Poxvirus entry and membrane fusion. Virology. 2006; 344(1):48–54. https://doi.org/10.1016/j.virol.2005.09.037 PMID: 16364735
27. Moser TS, Jones RG, Thompson CB, Coyne CB, Cherry S. A kinase RNAi screen identified AMPK as promoting poxvirus entry through the control of actin dynamics. PLoS Pathog. 2010; 6(6):e1000954.

28. Mercer J, Snijder B, Sacher R, Burkard C, Bleck CK, Stahlberg H, et al. RNAi screening reveals proteasome- and Cullin3-dependent stages in vaccinia virus infection. Cell Rep. 2012; 2(4):1036–47. https://doi.org/10.1016/j.celrep.2012.09.003 PMID: 23084750

29. Sivan G, Martin SE, Myers TG, Buehler E, Szymczyk KH, Ormanoglu P, et al. Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. Proc Natl Acad Sci U S A. 2013; 110(9):3519–24. https://doi.org/10.1073/pnas.1300708110 PMID: 23401514

30. Beard PM, Griffiths SJ, Gonzalez O, Haga IR, Pechenick Jowers T, Reynolds DK, et al. A loss of function analysis of host factors influencing vaccinia virus replication by RNA interference. PLoS One. 2014; 9(6):e98431. https://doi.org/10.1371/journal.pone.0098431 PMID: 24901222

31. Realegeno S, Puschnik AS, Kumar A, Goldsmith C, Burgado J, Sambhara S, et al. Monkeypox Virus Host Factor Screen Using Haploid Cells Identifies Essential Role of GAPC Complex in Extracellular Virus Formation. J Virol. 2017;91(11). https://doi.org/10.1128/JVI.00111-17 PMID: 28331092

32. Luteijn RD, van Diemen F, Blomen VA, Boer IGJ, Manikam Sadasivam S, van Kuppevelt TH, et al. A Genome-Wide Haploid Genetic Screen Identifies Heparan Sulfate-Associated Genes and the Macropinocytosis Modulator TMED10 as Factors Supporting Vaccinia Virus Infection. J Virol. 2019;93(13). https://doi.org/10.1128/JVI.02160-18 PMID: 30996093

33. Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 2014; 11(8):783–4.

34. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelson T, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014; 343(6166):84–7. https://doi.org/10.1126/science.1247005 PMID: 24336571

35. Krangel MS, Orr HT, Strominger JL. Assembly and maturation of HLA-A and HLA-B antigens in vivo. Cell. 1979; 18(4):979–91. https://doi.org/10.1016/0092-8674(79)90210-1 PMID: 93026

36. Feder JN, Giriike A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A Novel MHC Class I-Like Gene Is Mutated in Patients with Hereditary Hemochromatosis. Nat Genet. 1996; 13(4):399–408. https://doi.org/10.1038/ng0896-399 PMID: 8696333

37. Praetor A, Hunziker W. Beta(2)-Microglobulin is important for cell surface expression and pH-dependent IgG binding of human FcRn. J Cell Sci. 2002;115(Pt 11):2389–97.

38. Yamaguchi H, Hashimoto K. Association of MR1 protein, an MHC class I-related molecule, with beta(2)-microglobulin. Biochem Biophys Res Commun. 2002; 290(2):722–9.

39. Wang T, Birsoy K, Hughes NW, Krupczak KM, Post Y, Wei JJ, et al. Identification and characterization of essential genes in the human genome. Science. 2015; 350(6264):1096–101. https://doi.org/10.1126/science.aac7041 PMID: 26472758

40. Bertomeu T, Coulombe-Huntington J, Chatr-Aryamontri A, Bourdages KG, Coyaud E, Raught B, et al. A High-Resolution Genome-Wide CRISPR/Cas9 Viability Screen Reveals Structural Features and Contextual Diversity of the Human Cell-Essential Proteome. Mol Cell Biol. 2018;38(1). https://doi.org/10.1128/MCB.00302-17 PMID: 29038160

41. Lorenzo MM, Sanchez-Puig JM, Blasso R. Genes A27L and F13L as Genetic Markers for the Isolation of Recombinant Vaccinia Virus. Sci Rep. 2019; 9(1):15684.

42. Sanderson CM, Hollinshead M, Smith GL. The vaccinia virus A27L protein is needed for the microtubule-dependent transport of intracellular mature virus particles. J Gen Virol. 2000; 81(1):47–58. https://doi.org/10.1099/0022-1317-81-1-47 PMID: 10640541

43. Holzer FW, Falkner FG. Construction of a vaccinia virus deficient in the essential DNA repair enzyme uracil DNA glycosylase by a complementing cell line. J Virol. 1997; 71(7):4997–5002. https://doi.org/10.1128/JVI.71.7.4997-5002.1997 PMID: 9188564

44. Ricci PS, Schemer B, Kreil TR, Falkner FG, Holzer GW. Selection of recombinant MVA by rescue of the essential D4R gene. Virol J. 2011; 8:529. https://doi.org/10.1186/1743-422X-8-529 PMID: 22152060

45. Li W, Xu H, Xiao T, Cong L, Love ML, Zhang F, et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol. 2014; 15(12):554. https://doi.org/10.1186/s13059-014-0554-4 PMID: 25476604

46. Wang B, Wang M, Zhang W, Xiao T, Chen CH, Wu A, et al. Integrative analysis of pooled CRISPR genetic screens using MAGeCKFlute. Nat Protoc. 2019; 14(3):756–80. https://doi.org/10.1038/s41596-018-0113-7 PMID: 30710114

47. Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet. 2017; 49(12):1779–84. https://doi.org/10.1038/ng.3984 PMID: 29083409
48. Yu J, Silva J, Califano A. ScreenBEAM: a novel meta-analysis algorithm for functional genomics screens via Bayesian hierarchical modeling. Bioinformatics. 2016; 32(2):260–7. https://doi.org/10.1093/bioinformatics/btv556 PMID: 26415723

49. Grimbert P, Valanciute A, Audard V, Lang P, Guellaen G, Sahali D. The Filamin-A is a partner of Tc-mip, a new adapter protein involved in c-maf-dependent Th2 signaling pathway. Mol Immunol. 2004; 40(17):1257–61. https://doi.org/10.1016/j.molimm.2003.11.035 PMID: 15128042

50. Grimbert P, Valanciute A, Audard V, Pawlak L, Le gouvelo S, Lang P, et al. Truncation of C-mip (Tc-mip), a new proximal signaling protein, induces c-maf Th2 transcription factor and cytoskeleton reorganization. J Exp Med. 2003; 198(5):797–807.

51. Rintala-Dempsey AC, Rezvanpour A, Shaw GS. S100-anne xin complex es—structur al insights. FEBS J. 2008; 275(20):49 56–66. https://doi.org/10.1111/j.1742-4658.2008.06654.x PMID: 18795951

52. Liu Y, Myrvang HK, Dekker LV. Annexin A2 complexes with S100 proteins: structure, function and pharmacological manipulation. Br J Pharmacol. 2015; 172(7):1664–76. https://doi.org/10.1111/bph.12978 PMID: 25303710

53. Canales J, Cruz P, Díaz N, Riquelme D, Leiva-Salcedo E, Cerda O. K(+) Channel Tetramerization Domain 5 (KCTD5) Protein Regulates Cell Migration, Focal Adhesion Dynamics and Spreading through Modulation of Ca(2+) Signaling and Rac1 Activity. Cells. 2020; 9(10).

54. Bayon Y, Trinidad AG, de la Puerta ML, Del Carmen Rodriguez M, Bogetz J, Rojas A, et al. KCTD5, a putative substrate adaptor for cullin3 ubiquitin ligases. FEBS J. 2008; 275(15):39 00–10. https://doi.org/10.1111/j.1742-4658.2008.06537.x PMID: 18573101

55. Yu G, He QY. Reacto mePA: an R/Biocondu ctor package for reactome pathway analysis and visualiza tion. Mol Biosyst. 2016; 12(2):477–9. https://doi.org/10.1039/c5mb00663e PMID: 26661513

56. Liu Y, Myrvang HK, Dekker LV. Annexin A2 complexes with S100 proteins: structure, function and phar macological manipulation. Br J Pharmacol. 2015; 172(7):1664–76. https://doi.org/10.1111/bph.12978 PMID: 25303710
68. Gay CM, Balaji K, Byers LA. Giving AXL the axe: targeting AXL in human malignancy. Br J Cancer. 2017; 116(4):415–23. https://doi.org/10.1038/bjc.2016.428 PMID: 28072762

69. Mattila PK, Lappalainen P. Filopodia: molecular architecture and cellular functions. Nat Rev Mol Cell Biol. 2008; 9(6):446–54. https://doi.org/10.1038/nrm2406 PMID: 1846790

70. Manni S, Carrino M, Semenzato G, Piazza F. Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance. Int J Mol Sci. 2018; 19(5). https://doi.org/10.3390/ijms19051512 PMID: 29783691

71. Apeleth L, Quintana FJ, Pot C, Jollier N, Xiao S, Kumar D, et al. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol. 2010; 11(9):854–61. https://doi.org/10.1038/ni.1912 PMID: 20676095

72. Pot C. Aryl hydrocarbon receptor controls regulatory CD4+ T cell function. Swiss Med Wkly. 2012; 142: w13592. https://doi.org/10.4414/smw.2012.13592 PMID: 22653785

73. Ollero M, Sahali D. The Enigmatic Emerging Role of the C-Maf Inducing Protein in Cancer. Diagnostics (Basel). 2021; 11(4). https://doi.org/10.3390/diagnostics11040666 PMID: 33917766

74. Monteiro P, Gilot D, Le Ferrec E, Lecureur V, N'Diaye M, Le Vee M, et al. AhR- and c-maf-dependent induction of beta7-integrin expression in human macrophages in response to environmental polycyclic aromatic hydrocarbons. Biochem Biophys Res Commun. 2007; 358(2):442–8. https://doi.org/10.1016/j.bbrc.2007.04.111 PMID: 17490615

75. Triantafilou M, Triantafilou K, Wilson KM, Takada Y, Fernandez N, Stanway G. Involvement of beta2-microglobulin and integrin alphavbeta3 molecules in the coxsackievirus A9 infectious cycle. J Gen Virol. 1999; 80 (Pt 10):2591–600. https://doi.org/10.1099/0022-1317-80-10-2591 PMID: 10573151

76. Heikkila O, Susi P, Tevaluoto T, Harma H, Marjomaki V, Hyyppia T, et al. Internalization of coxsackievirus A9 is mediated by beta2-microglobulin, dynamin, and Arf6 but not by caveolin-1 or clathrin. J Virol. 2010; 84(7):3666–81. https://doi.org/10.1128/JVI.01340-09 PMID: 20898652

77. Heikkila O, Merilahti P, Hakainen M, Karelehto E, Alanko J, Sukki M, et al. Integrins are not essential for entry of coxsackievirus A9 into SW480 human colon adenocarcinoma cells. Virol J. 2016; 13(1):171. https://doi.org/10.1186/s12985-016-0619-y PMID: 27756316

78. Huang CY, Lu TY, Bair CH, Chang YS, Jwo JK, Chang W. A novel cellular protein, VPEF, facilitates vaccinia virus penetration into HeLa cells through fluid phase endocytosis. J Virol. 2008; 82(16):7988–99. https://doi.org/10.1128/JVI.00894-08 PMID: 18550675

79. Zhao X, Zhang G, Liu S, Chen X, Peng R, Dai L, et al. Human Neonatal Fc Receptor Is the Cellular Uncoating Receptor for Enterovirus B. Cell. 2019; 177(6):1553–65 e16. https://doi.org/10.1016/j.cell.2019.04.035 PMID: 31104841

80. Morosky S, Wells AI, Lemon K, Evans AS, Schamus S, Bakkenist CJ, et al. The neonatal Fc receptor is a pan-echovirus receptor. Proc Natl Acad Sci U S A. 2019; 116(9):3758–63. https://doi.org/10.1073/pnas.1817341116 PMID: 30808762

81. Randazzo PA, Andrade J, Miura K, Brown MT, Long YQ, Stauffer S, et al. The Arf GTPase-activating protein ASAP1 regulates the actin cytoskeleton. Proc Natl Acad Sci U S A. 2000; 97(8):4011–6. https://doi.org/10.1073/pnas.070552297 PMID: 10725410

82. Lorenzo MM, Galindo I, Blasco R. Construction and isolation of recombinant vaccinia virus using genetic markers. Methods Mol Biol. 2004; 269:15–30. https://doi.org/10.1385/1-59259-789-0:015 PMID: 15114004

83. Earl PL, Cooper N, Wyatt LS, Moss B, Carroll MW. Preparation of cell cultures and vaccinia virus stocks. Curr Protoc Mol Biol. 2001, Chapter 16:Unit16

84. Torres R, Garcia A, Paya M, Ramirez JC. Non-integrative lentivirus drives high-frequency cre-mediated cassette exchange in human cells. PLoS One. 2011; 6(5):e19794. https://doi.org/10.1371/journal.pone.0019794 PMID: 21625434

85. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 1998; 72(12):9873–80. https://doi.org/10.1128/JVI.72.12.9873-9880.1998 PMID: 9811723

86. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998; 72(11):8463–71. https://doi.org/10.1128/JVI.72.11.8463-8471.1998 PMID: 9765382

87. Chiem K, Lorenzo MM, Rangel-Moreno J, Garcia-Hernandez ML, Park JG, Nogales A, et al. Bi-Reporter Vaccinia Virus for Tracking Viral Infections In Vitro and In Vivo. Microbiol Spectr. 2021; 9(3): e0160121. https://doi.org/10.1128/Spectrum.01601-21 PMID: 34817228

88. Conant D, Hsiau T, Rossi N, Oki J, Maures T, Waite K, et al. Inference of CRISPR Edits from Sanger Trace Data. CRISPR J. 2022; 5(1):123–30.
89. Chang HW, Yang CH, Luo YC, Su BG, Cheng HY, Tung SY, et al. Vaccinia viral A26 protein is a fusion suppressor of mature virus and triggers membrane fusion through conformational change at low pH. PLoS Pathog. 2019;15(6):e1007826. https://doi.org/10.1371/journal.ppat.1007826 PMID: 31220181

90. Bisht H, Weisberg AS, Moss B. Vaccinia virus I1 protein is required for cell entry and membrane fusion. J Virol. 2008;82(17):8687–94. https://doi.org/10.1128/JVI.00852-08 PMID: 18596103

91. Vanderplaschen A, Smith GL. A novel virus binding assay using confocal microscopy: demonstration that the intracellular and extracellular vaccinia virions bind to different cellular receptors. J Virol. 1997;71(5):4032–41. https://doi.org/10.1128/JVI.71.5.4032-4041.1997 PMID: 9094681